Positive News SentimentPositive NewsNASDAQ:TLIS Talis Biomedical (TLIS) Stock Price, News & Analysis → Biden Nomination CANCELED? (From The Freeport Society) (Ad) Free TLIS Stock Alerts $9.20 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$9.18▼$9.2150-Day Range$8.00▼$9.3352-Week Range$4.35▼$9.60Volume1,354 shsAverage Volume7,200 shsMarket Capitalization$16.74 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Talis Biomedical alerts: Email Address Talis Biomedical MarketRank™ Stock AnalysisAnalyst RatingSell1.00 Rating ScoreUpside/Downside45.7% Downside$5.00 Price TargetShort InterestHealthy0.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.81 out of 5 starsMedical Sector848th out of 924 stocksAnalytical Instruments Industry27th out of 29 stocks 0.5 Analyst's Opinion Consensus RatingTalis Biomedical has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTalis Biomedical has received no research coverage in the past 90 days.Read more about Talis Biomedical's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.76% of the float of Talis Biomedical has been sold short.Short Interest Ratio / Days to CoverTalis Biomedical has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Talis Biomedical has recently decreased by 5.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTalis Biomedical does not currently pay a dividend.Dividend GrowthTalis Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TLIS. Previous Next 3.8 News and Social Media Coverage News SentimentTalis Biomedical has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Talis Biomedical this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Talis Biomedical to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Talis Biomedical insiders have not sold or bought any company stock.Percentage Held by Insiders46.00% of the stock of Talis Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.77% of the stock of Talis Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Talis Biomedical's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Talis Biomedical is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Talis Biomedical is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTalis Biomedical has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Talis Biomedical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About Talis Biomedical Stock (NASDAQ:TLIS)Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.Read More TLIS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLIS Stock News HeadlinesMay 10, 2024 | investing.comTalis Biomedical Corp (TLIS)May 8, 2024 | investorplace.comTLIS Stock Earnings: Talis Biomedical Reported Results for Q1 2024March 31, 2024 | finance.yahoo.comTalis Biomedical Corporation (TLIS)February 16, 2024 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Talis Biomedical CorporationFebruary 15, 2024 | finance.yahoo.comTLIS Feb 2024 2.500 putNovember 14, 2023 | bizjournals.comPeninsula diagnostics company to close Redwood City labs and offices, pursue 'strategic alternatives'November 14, 2023 | finanznachrichten.deTalis Biomedical Corporation: Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve CashNovember 14, 2023 | msn.comLICY, BTAI and HROW among mid-day moversNovember 14, 2023 | msn.comTalis reviewing strategic alternatives, stock rallies 35%November 14, 2023 | msn.comWhy Talis Biomedical (TLIS) Stock Is Exploding HigherNovember 14, 2023 | finance.yahoo.comTalis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve CashAugust 16, 2023 | msn.comBTIG Maintains Talis Biomedical (TLIS) Sell RecommendationAugust 16, 2023 | markets.businessinsider.comBTIG Maintains Sell Rating for Talis Biomedical: Here's What You Need To KnowAugust 11, 2023 | finance.yahoo.comTalis Biomedical Announces Second Quarter 2023 Financial Results and Business UpdateAugust 9, 2023 | benzinga.comA Preview Of Talis Biomedical's EarningsAugust 3, 2023 | finance.yahoo.comTalis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023August 2, 2023 | finance.yahoo.comTalis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)August 1, 2023 | uk.finance.yahoo.comTLIS - Talis Biomedical CorporationJuly 24, 2023 | finance.yahoo.comTalis Biomedical Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 5, 2023 | finance.yahoo.comTalis Biomedical Announces 1-for-15 Reverse Stock SplitMay 23, 2023 | finance.yahoo.comTalis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors, Announces Former Genomic Health CEO Kim Popovits as Lead Independent DirectorMay 12, 2023 | finanznachrichten.deTalis Biomedical Corporation: Talis Biomedical Announces Business Update and First Quarter 2023 Financial ResultsMay 11, 2023 | seekingalpha.comTalis Biomedical reports Q1 resultsMay 11, 2023 | msn.comTalis Biomedical: Q1 Earnings InsightsMay 9, 2023 | benzinga.comTalis Biomedical Corporation (TLIS) Investor News: Robbins LLP Reminds Investors it is Investigating TLIS on Behalf of ShareholdersSee More Headlines Receive TLIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/02/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:TLIS CUSIPN/A CIK1584751 Webtalis.bio Phone650-433-3000FaxN/AEmployees99Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside-45.7%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($31.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,010,000.00 Net Margins-5,784.73% Pretax Margin-5,784.73% Return on Equity-75.40% Return on Assets-56.16% Debt Debt-to-Equity RatioN/A Current Ratio7.51 Quick Ratio7.51 Sales & Book Value Annual Sales$2.13 million Price / Sales7.86 Cash FlowN/A Price / Cash FlowN/A Book Value$31.11 per share Price / Book0.30Miscellaneous Outstanding Shares1,820,000Free Float984,000Market Cap$16.74 million OptionableNo Data Beta1.66 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert Kelley MBA (Age 52)CEO & Director Comp: $852.36kDr. Andrew A. Lukowiak Ph.D. (Age 51)President & Chief Scientific Officer Comp: $904.9kDr. Rustem F. Ismagilov Ph.D. (Age 50)Co-Founder & Director Comp: $53.95kMs. Rebecca Markovich (Age 50)Interim Chief Financial Officer Comp: $379.23kMr. Liang Li Ph.D.Co-Founder and Director of Technology & StrategyMs. Emily FaucetteSenior Vice President of Corporate Communications & Investor RelationsMs. Jill GreenSenior Vice President of LegalMr. Matthew PepeVice President of Human ResourceMs. Margaret Barrett M.S.ControllerGillian GreenCompany SecretaryMore ExecutivesKey CompetitorsLucid DiagnosticsNASDAQ:LUCDPrenetics GlobalNASDAQ:PRERapid Micro BiosystemsNASDAQ:RPIDAccelerate DiagnosticsNASDAQ:AXDXSingular Genomics SystemsNASDAQ:OMICView All Competitors TLIS Stock Analysis - Frequently Asked Questions Should I buy or sell Talis Biomedical stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Talis Biomedical in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street analysts is that investors should "sell" TLIS shares. View TLIS analyst ratings or view top-rated stocks. What is Talis Biomedical's stock price target for 2024? 1 equities research analysts have issued 12 month price targets for Talis Biomedical's shares. Their TLIS share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests that the stock has a possible downside of 45.7%. View analysts price targets for TLIS or view top-rated stocks among Wall Street analysts. How have TLIS shares performed in 2024? Talis Biomedical's stock was trading at $7.45 at the start of the year. Since then, TLIS shares have increased by 23.5% and is now trading at $9.20. View the best growth stocks for 2024 here. When is Talis Biomedical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our TLIS earnings forecast. How were Talis Biomedical's earnings last quarter? Talis Biomedical Co. (NASDAQ:TLIS) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($7.15) EPS for the quarter. The company had revenue of $0.07 million for the quarter. Talis Biomedical had a negative trailing twelve-month return on equity of 75.40% and a negative net margin of 5,784.73%. When did Talis Biomedical's stock split? Shares of Talis Biomedical reverse split on the morning of Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Talis Biomedical IPO? Talis Biomedical (TLIS) raised $150 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Talis Biomedical? Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TLIS) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBill Clinton Backing Biden Replacement???The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talis Biomedical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
